Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$47.20 USD

47.20
1,183,987

+0.21 (0.45%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $47.23 +0.03 (0.06%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal

by Zacks Equity Research

AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.

Zacks Equity Research

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

by Zacks Equity Research

SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.

Zacks Equity Research

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

by Zacks Equity Research

Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.

Zacks Equity Research

Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?

by Zacks Equity Research

Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.

Zacks Equity Research

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Zacks Equity Research

ALKS or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALKS vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

by Zacks Equity Research

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

Zacks Equity Research

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

by Zacks Equity Research

Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.

Zacks Equity Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

by Zacks Equity Research

Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.

Zacks Equity Research

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

by Zacks Equity Research

ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.